FDA Recall Open, Classified

HemosIL ReadiPlasTin (20 mL), Part number 0020301400. An in vitro diagnostic thromboplastin reagent.

Recall: Z-0276-2022 · Initiated October 13, 2021

Recall

Recall Number
Z-0276-2022
Event Number
88930
Firm
Instrumentation Laboratory
FEI Number
1217183
Product Code
GJS
Status
Open, Classified
Root Cause
Under Investigation by firm
Initiated
October 13, 2021
Posted
November 23, 2021
Address
180 Hartwell Rd, Bedford, MA, 01730-2443

Description

HemosIL ReadiPlasTin (20 mL), Part number 0020301400. An in vitro diagnostic thromboplastin reagent.

Reason

The firm has received customer reports of performance issues with the affected lot, including increased imprecision, out of range quality controls, and prolonged sample results. If quality controls are not performed or do not pass for each vial of reagent, there is a potential risk of reporting an erroneous result.

Action

On October 13, 2021, the firm sent customers Urgent Medical Device Removal letters via email. These emails were followed by certified letters sent starting the same day. ***On February 17, 2022, the firm expanded the recall to include an additional lot of product.*** The customers were provided with instructions to run quality controls with each vial. Customers should discard any vials with failed quality controls. For technical questions, please contact the IL Technical Support Center at 1-800-678-0710, Option # 2 (ACL Coagulation Products). For alternate lot availability questions, please contact your IL Customer Service Representative at 1-800-955-9525, Option # 0.

Distribution

Worldwide distribution - US Nationwide distribution in the states of AZ, CA, IA, IL, KS, ME, MI, NC, NY, OK, SC, and VA. The countries of Canada, Chile, China, Costa Rica, Italy, Japan, and South Korea. ***Updated 3/3/22*** Expansion includes states of IN, MN, and NC.

Quantity

5828 kits (310 US)